RxDoctor Payments Data

Bilal Sadiq, MD

Hospitalist · Little Rock, ARNPI 1275791402

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $191 of the $221 with a category attached, or 86.4%. 9 manufacturers reported payments, led by Astellas Pharma US Inc at 31.9% of the total. Reporting peaked in 2019 at $83 and has fallen 78.7% since, to $18 in 2024.

$221in general payments, 2019–2025

Across 11 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$70
  • AbbVie$26
  • Kerecis Limited$25
  • AstraZeneca$22
  • Pfizer$19
  • Actelion Pharmaceuticals US, Inc.$18
  • plus $41 from 3 others

What the payments were for

  • Food & beverage$19186%
  • Education$3014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$221 in reported general payments places this provider in the 60th percentile of 125 hospitalist providers in Arkansas.

See all hospitalist providers in Arkansas

Medicare billing

Part B allowed, 2024
$490,061
Medicare patients
1,118
Services billed
5,606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$74,663
IngrezzaValbenazine Tosylate12$49,316
Invega SustennaPaliperidone Palmitate16$45,500
JardianceEmpagliflozin48$14,137
XareltoRivaroxaban46$12,363
MounjaroTirzepatide11$12,114
JanuviaSitagliptin Phosphate31$9,562
EntrestoSacubitril/Valsartan26$8,467
FarxigaDapagliflozin Propanediol25$8,415
Divalproex Sodium121$6,838
LinzessLinaclotide12$6,652
GemtesaVibegron24$5,463
Sucralfate63$5,399
Atorvastatin Calcium448$5,245
AuryxiaFerric Citrate15$5,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$74,663265 claims
AstraZenecaFarxiga$22$8,41525 claims
AbbVieLinzess$26$6,65212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 125 hospitalist providers in Arkansas.

Other hospitalist in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →